This roundtable series evaluates the use of therapies such as monoclonal antibodies in advanced non–small cell lung cancer with high PD-L1 expression, as discussed by participants at virtual live events.
Part 1: Challenges of Choosing Single-Agent Immunotherapy for NSCLC
During a live virtual event, Ravi Salgia, MD, PhD, discussed the use of immune checkpoint inhibitor monotherapy for a patient with non–small cell lung cancer with very high PD-L1 expression with participants.
Part 2: Discussing Brain Metastases and Immunotherapy Duration in NSCLC
During a live virtual event, Ravi Salgia, MD, PhD, discussed treatment considerations for a patient with non–small cell lung cancer with a brain metastasis.
Immunotherapies Offer Alternatives to Chemotherapy for PD-L1–High Lung Cancer
During a Targeted Oncology live virtual event, Martin F. Dietrich, MD, PhD, discussed data from 3 trials of immunotherapy agents for patients with non–small cell lung cancer with high PD-L1 expression.
Exploring Subset Analyses in the EMPOWER-Lung 1 Trial for NSCLC
During a live virtual event, Martin F. Dietrich, MD, PhD, discussed the results of the EMPOWER-Lung 1 and EMPOWER-Lung 3 trials of cemiplimab for non–small cell lung cancer.